- Conditions
- Hyperphagia in Prader-Willi Syndrome
- Interventions
- Carbetocin, Placebo
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 5 Years to 30 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Orange, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Postpartum Hemorrhage
- Interventions
- Carbetocin, Placebo, Placebo and Moxifloxacin
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Hyperphagia in Prader-Willi Syndrome
- Interventions
- Carbetocin
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 5 Years to 30 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Orange, California + 16 more
- Conditions
- Hyperphagia in Prader-Willi Syndrome
- Interventions
- FE 992097, Placebo
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • Mineola, New York • Nashville, Tennessee
- Conditions
- Prader-Willi Syndrome
- Interventions
- 3.2 mg intranasal carbetocin, 9.6 mg intranasal carbetocin, placebo
- Drug
- Lead sponsor
- Levo Therapeutics, Inc.
- Industry
- Eligibility
- 7 Years to 18 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more